9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Estimated reading time: < 1 min

Condition: Part A and B: Advanced Solid Malignancies

Estimated Enrollment: 65

Gender: All

Min Age: 20 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Adverse event,  ,  ,

Interventions: Tremelimumab, MEDI4736

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Masking: None (Open Label), Primary Purpose: Other,

Primary Completion Date: January 27, 2017

Completion Date: January 27, 2017

Last  Posted Date: December 12, 2018

Location: Research Site, Bunkyo-ku, Japan

Website Link: https://ClinicalTrials.gov/show/NCT02141347

Was this article helpful?
Dislike 0